Blockchain Registration Transaction Record
Tevard Biosciences Appoints Dr. Elisabeth Gardiner as CSO to Advance tRNA Therapies
Tevard Biosciences names Dr. Elisabeth Gardiner as CSO to lead tRNA-based therapies for genetic diseases, marking a leap towards curing rare genetic disorders.

This news is significant as it highlights a major step forward in the treatment of genetic diseases through tRNA-based therapies. Dr. Gardiner's appointment and Tevard's innovative platform offer hope for patients with conditions like Duchenne Muscular Dystrophy, where traditional treatments have fallen short. The potential for these therapies to address a wide range of genetic disorders could revolutionize medicine, providing durable and precise treatments for diseases previously considered incurable.
Blockchain | Details |
---|---|
Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
Transaction ID | 0x980ba3ab418165f0eda6793d5bd7c875e40987e611b5de751460b367ccce1fd2 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | jazzIG73-5531f7a2cc4f99a05e4b3782ae579766 |